The Founding Era: The Pioneer of Gene Therapy (1998–2011)

In 1998, uniQure was founded under its original name, Amsterdam Molecular Therapeutics (AMT), by a group of visionary scientists in the Netherlands. At a time when gene therapy was largely theoretical and facing severe clinical setbacks globally, AMT pioneered the development of Adeno-Associated Virus (AAV) vectors to deliver functional copies of genes directly into human cells. This foundational work laid the structural groundwork for the entire modern field of genomic medicine.

By 2007, the company listed on the Euronext Amsterdam exchange to fund its high-stakes clinical pipelines. Its primary research engine focused on ultra-rare metabolic disorders, specifically targeting Lipoprotein Lipase Deficiency (LPLD)—a severe genetic disease that prevents patients from breaking down dietary fats, leading to life-threatening bouts of pancreatitis.

Through years of refining proprietary insect-cell manufacturing platforms (the baculovirus expression system), the company proved that complex viral vectors could be standardized, replicated, and manufactured to meet rigorous regulatory criteria.

The Breakthrough: Glybera and the Dawn of Genomic Commercialization (2012–2014)

As the company rebranded to uniQure in 2012 to reflect its global ambitions, it achieved a historic milestone that fundamentally transformed the biotechnology landscape.

In late 2012, the European Commission granted regulatory approval to Glybera, uniQure’s treatment for LPLD. This was a monumental pivot in medical history—Glybera became the world’s first approved gene therapy in the Western world. This achievement effectively proved that gene therapy was no longer science fiction; it was a viable, commercial reality that could cure a disease with a single, one-time dose.

While Glybera faced commercial hurdles due to its million-dollar price tag and the extreme rarity of the disease, its clinical approval served as the blueprint for the entire industry. It established the global regulatory pathway for advanced therapy medicinal products (ATMPs), defining how regulatory bodies would evaluate, test, and approve genetic medicines for decades to come.

Pushing Frontiers: Modular Platforms & The Liver-Directed Pivot (2015–2019)

Recognizing that ultra-rare orphan indications were commercially challenging, uniQure executed a definitive strategic pivot under a refreshed executive team. The company redirected its core proprietary AAV5 vector technology toward high-impact, larger-scale target organs—specifically the liver and the central nervous system.

The cornerstone of this new era was Etranacogene dezaparvovec, an investigational gene therapy designed to treat Hemophilia B, a debilitating genetic bleeding disorder caused by a lack of blood clotting Factor IX.

During this period, uniQure built a massive, state-of-the-art manufacturing facility in Lexington, Massachusetts. This facility was highly unique: it allowed uniQure to control its entire production chain internally, bridging laboratory-scale molecular design with commercial-scale industrial output. By standardizing their AAV5 expression system, they could swap out genetic payloads while using the exact same manufacturing infrastructure, drastically lowering production risks.

The Blockbuster Validation & The "Great Alliance" (2020–2022)

At the start of the decade, uniQure’s high-stakes industrial strategy paid off, leading to one of the most significant validation points in biotechnology history.

2020 – The Strategic Alliance: In a massive validation of uniQure's research engine, global biopharma giant CSL Behring acquired the exclusive global commercialization rights to uniQure's Hemophilia B gene therapy program for $450 million upfront, alongside over $1.5 billion in potential milestones and substantial royalties. This alliance allowed uniQure to retain its identity as a lean research and manufacturing powerhouse while leveraging CSL's massive global commercial distribution footprint.

2022 – FDA Historic Approval: In November 2022, the therapy—now named Hemgenix—received official FDA approval. Clinical trials proved that a single infusion eliminated the need for routine, lifelong clotting factor infusions for the vast majority of patients. Hemgenix made history as the first FDA-approved gene therapy for Hemophilia B, securing uniQure's position as an elite architect of functional, life-altering genomic cures.

Next-Gen Biotechnology: Silencing Disease & The CNS Pipeline (2023–Present)

Today, uniQure has fundamentally redefined its research frontier by shifting from simple gene replacement to advanced gene silencing and targeted neurological therapeutics.

The primary target of this modern era is AMT-130, the company's proprietary investigational gene therapy for Huntington's Disease—a fatal, inherited neurodegenerative disorder with no current cure. AMT-130 utilizes an advanced microRNA (miRNA) mechanism delivered directly to the brain to intercept and safely inhibit the production of the toxic mutant huntingtin protein before it can destroy neural pathways.

By pushing into the central nervous system (CNS) and advancing clinical candidates for severe conditions like Temporal Lobe Epilepsy and Amyotrophic Lateral Sclerosis (ALS), uniQure continues to operate at the cutting edge of modern med-tech. They are transitioning from a pioneer of early genetic concepts into a highly specialized, global biotechnology engine designed to intercept severe human disease at the absolute corporate DNA level

UniQure

TerraByte